Beneficence in research is the ethical obligation to maximize benefits and minimize harm to participants. It is one of three core principles outlined in the Belmont Report, the foundational U.S. document on research ethics published in 1979. In practice, beneficence shapes how studies are designed, reviewed, and monitored, requiring researchers to carefully weigh what participants stand to gain against the risks they face.
Where the Principle Comes From
The idea of beneficence in medicine dates back to Hippocrates and the ancient directive “to help and do no harm.” But it wasn’t formally codified for research until the late 1970s. The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research developed the Belmont Report over several years of deliberation, submitting the final version in September 1978. It was publicly listed in the Federal Register in April 1979 and remains one of the most important bioethics policy documents in the United States.
The report identified three principles: Respect for Persons, Beneficence, and Justice. During the commission’s work, theologian Karen Lebacqz originally proposed seven separate principles, including distinct concerns for benefiting individuals, benefiting society, minimizing harm to subjects, and minimizing harm to others. Commissioner Joseph Brady, a psychiatrist, condensed these into a simpler framework. In the final report, beneficence was defined as having two components: a concern to benefit participants and a concern to minimize harm to them.
What Beneficence Actually Requires
Beneficence is a positive obligation. It doesn’t just ask researchers to avoid hurting people. It requires them to actively promote participants’ welfare, protect their rights, prevent harm, and remove conditions that could cause harm. This is an important distinction: the principle goes beyond passive caution into active responsibility for the well-being of everyone enrolled in a study.
In practical terms, this means researchers must design studies that use the safest procedures possible, collect only the data they actually need, build in safeguards like data monitoring boards that can halt a trial if problems emerge, and ensure participants understand what they’re agreeing to. If a study involves a medical procedure, researchers should use methods already being performed for the participant’s care whenever feasible, rather than adding unnecessary interventions.
Beneficence vs. Non-Maleficence
You’ll often see beneficence paired with a related but separate concept: non-maleficence. Non-maleficence is the obligation not to harm. It supports straightforward moral rules like do not cause pain, do not cause suffering, and do not deprive people of what they need to live well. Beneficence goes further. Where non-maleficence says “don’t hurt anyone,” beneficence says “take steps to help them.”
Think of it this way: a researcher who avoids using a dangerous procedure is practicing non-maleficence. A researcher who redesigns the study so participants also receive access to a beneficial screening or treatment is practicing beneficence. Both matter, but beneficence is the more demanding standard because it asks for positive action, not just restraint.
How Ethics Boards Apply It
In the United States, the principle of beneficence is built directly into federal regulations. The Common Rule (45 CFR Part 46) governs research involving human subjects, and it explicitly requires that all decisions remain consistent with the ethical principles of the Belmont Report. Before any federally funded study can begin, an Institutional Review Board (IRB) must confirm two things related to beneficence: that risks to participants are minimized through sound research design, and that remaining risks are reasonable in relation to anticipated benefits.
IRBs evaluate only the risks and benefits that come from the research itself, not from treatments participants would receive regardless of whether they enrolled. There is no formula or algorithm for making this determination. Instead, review boards often rely on what’s called the “informed clinician test”: would a knowledgeable clinician recommend that a potential participant undergo this intervention? If yes, the potential benefits are considered to justify the risks. If not, the study needs to be redesigned or rejected.
When a study does pose risks that outweigh its direct benefits to participants (which is common in early-phase research), IRBs then ask whether those risks are minimal, meaning no greater than what people ordinarily encounter in daily life, and whether they’re justified by the importance of the knowledge the study could produce. This layered assessment ensures beneficence stays at the center of the approval process even when a study can’t directly help its participants.
Protecting Vulnerable Populations
Beneficence becomes especially complex when research involves people who may have limited ability to protect their own interests: children, prisoners, pregnant women, or individuals with cognitive disabilities. Federal regulations include specific additional protections for these groups under Subparts B, C, and D of the Common Rule.
For people with cognitive or communicative vulnerabilities, protections might include plain-language consent forms, additional educational materials, or the use of interpreters and translated documents. For prisoners, the concern shifts to ensuring that the consent process insulates participants from the pressures of a hierarchical institutional system, so their decision to enroll is genuinely voluntary. The underlying tension is real: the principle of justice says the benefits of research should be available to everyone, including vulnerable groups, but beneficence demands extra caution to make sure those same groups aren’t exploited or exposed to disproportionate risk.
International Standards
Beneficence isn’t only an American concept. The Declaration of Helsinki, originally adopted by the World Medical Association in 1964 and most recently revised in October 2024, sets international ethical standards for medical research involving human participants. The declaration reaffirms that the rights and interests of individual research participants can never be outweighed by the goals of a study, no matter how important those goals may be.
The 2024 revision expanded on several themes connected to beneficence, including fair distribution of risks and benefits, community engagement, responsible inclusion of individuals with vulnerabilities, and obligations to provide post-trial access to treatments that prove effective. It also calls on researchers to actively engage participants and their communities in expressing their priorities and values, rather than making those judgments on their behalf.
New Challenges in Data and AI Research
Applying beneficence gets more complicated when research doesn’t involve a physical intervention at all. In large-scale data mining and artificial intelligence research, participants may never meet a researcher or even know their information is being used. The risks shift from physical harm to things like privacy violations, discriminatory outcomes, and biased algorithms that could affect entire populations.
AI and machine learning models can carry bias from their training data, from the way developers select which features to prioritize, from institutional practice patterns, and from changes in technology or disease patterns over time. These biases can lead to unfair or harmful outcomes for specific groups, which directly conflicts with the obligation of beneficence. Ensuring that AI systems in medicine remain fair, transparent, and genuinely beneficial to all patients is one of the most active areas of ethical discussion in research today.